Dashboard
Manage Tickers

IMMP IMMUTEP Ltd

Nasdaq immutep.com


$ 1.87 $ -0.08 (-4.1 %)    

Friday, 31-Oct-2025 14:42:02 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 629.64 $ -4.36 (-0.69 %)
DIA $ 476.03 $ 0.15 (0.03 %)
SPY $ 682.58 $ -2.49 (-0.36 %)
TLT $ 90.24 $ -0.32 (-0.35 %)
GLD $ 368.00 $ -2.38 (-0.64 %)
$ 1.92
$ 1.95
$ 1.86 x 5,055
$ 1.88 x 200
$ 1.87 - $ 1.95
$ 1.32 - $ 2.71
158,880
na
280.39M
$ 1.32
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

immuteps-reports-eftisarc-neo-phase-ii-trial-data-the-investigator-initiated-phase-ii-study-evaluating-eftilagimod-alfa-with-radiotherapy-plus-keytruda-the-neoadjuvant-setting-for-resectable-soft-tissue-sarcoma-met-its-primary-endpoint
Immutep's Reports EFTISARC-NEO Phase II Tr...
10/20/2025 12:10:07

immutep-announces-us-fda-has-provided-feedback-confirming-successful-completion-of-project-optimus-requirements-and-agreement-on-30mg-as-the-optimal-biological-dose-for-its-lead-immunotherapy-candidate-eftilagimod-alfa
Immutep Announces U.S. FDA Has Provided Fe...
10/13/2025 12:07:11

Confirmation of 30mg efti as optimal biological dose relevant for Immutep's oncology pipeline and potential future Biologic...

immutep-announces-its-global-phase-iii-tacti-004-trial-for-advanced-non-small-cell-lung-cancer-has-surpassed-key-milestone-with-over-170-patients-enrolled-and-randomized
Immutep Announces Its Global Phase III TAC...
10/09/2025 12:07:46

Global Phase III trial has enrolled and randomised over 170 patients, reaching an important milestone as this is above the amou...

immutep-initiates-phase-ii-trial-of-efti-as-monotherapy-and-with-chemotherapy-for-early-stage-hrher2--breast-cancer
Immutep Initiates Phase II Trial Of Efti A...
09/22/2025 12:17:16

GW Cancer Center to initiate Phase II trial evaluating neoadjuvant efti as monotherapy and in combination with chemotherapy pri...

immutep-to-present-phase-ii-eftisarc-neo-trial-data-on-efti--keytruda-combo-in-soft-tissue-sarcoma-at-ctos-2025
Immutep To Present Phase II EFTISARC-NEO T...
09/08/2025 12:12:50

Data to be presented in the Immunotherapy & Cell Therapy in Sarcoma: Emerging Frontiers session at the Connective Tissue On...

immutep-says-fda-agreed-on-potential-of-efti-plus-keytruda-in-head-and-neck-cancer-with-cps-1
Immutep Says FDA Agreed On Potential Of Ef...
08/05/2025 12:17:37

immutep-to-present-phase-iii-tacti-004-trial-design-for-efti-combo-therapy-at-2025-wclc
Immutep To Present Phase III TACTI-004 Tri...
07/29/2025 12:14:45

Immutep Limited ((ASX: IMM, NASDAQ:IMMP) ("Immutep" or "the Company"), a late-stage immunotherapy company targe...

immutep-to-present-abstracts-evaluating-first-in-class-mhcclass-ii-agonist-eftilagimod-alfa-at-european-society-for-medical-oncology-congress-2025
Immutep To Present Abstracts Evaluating Fi...
07/28/2025 12:05:46

immutep-announces-initial-efficacy-data-and-continued-safety-data-from-placebo-controlled-double-blind-first-in-human-phase-i-study-evaluating-imp761-lag-3-agonist-antibody-for-autoimmune-diseases
Immutep Announces Initial Efficacy Data An...
06/23/2025 12:06:37

Initial pharmacological data from placebo-controlled, double-blind Phase I study shows significant T cell suppression and a fav...

immutep-announces-eftisarc-neo-phase-ii-trial-of-efti-with-radiotherapy--keytruda-met-primary-endpoint
Immutep announces EFTISARC-NEO Phase II Tr...
05/27/2025 12:04:15

Core News & Articles
12 Health Care Stocks Moving In Wednesday'...
05/21/2025 21:06:07

immutep-reports-61-response-rate-in-lung-cancer-trial-with-keytruda-based-triple-combo
Immutep Reports 61% Response Rate In Lung ...
05/15/2025 19:50:04

Immutep's efti combo with Keytruda and chemo shows a 60.8% response rate in lung cancer trial, with strong efficacy across ...

immutep-announces-announces-that-a-608-response-rate-and-902-disease-control-rate-according-to-recist-has-been-achieved-in-the-investigator-initiated-insight-003-trial-as-of-the-data-cut-off-date-of--may-6
Immutep Announces Announces That A 60.8% R...
05/15/2025 12:17:53

ichor-holdings-posts-weak-earnings-joins-fabrinet-vertex-pharmaceuticals-and-other-big-stocks-moving-lower-in-tuesdays-pre-market-session
Ichor Holdings Posts Weak Earnings, Joins ...
05/06/2025 12:08:19

Core News & Articles
12 Health Care Stocks Moving In Monday's I...
05/05/2025 17:05:51

immutep-announces-an-median-overall-survival-of-176-months-has-been-achieved-in-cohort-b-of-the-tacti-003-phase-iib-trial
Immutep Announces An Median Overall Surviv...
05/05/2025 12:03:30

Complementary nature of these two immunotherapies leads to excellent 17.6-month median Overall Survival in head and neck cancer...

immutep-announces-first-patient-dosed-in-tacti-004-phase-iii-trial-for-advanced-non-small-cell-lung-cancer-combining-eftilagimod-alfa-with-keytruda-and-chemotherapy
Immutep Announces First Patient Dosed In T...
03/25/2025 12:08:20

First patient safely dosed at Calvary Mater Newcastle Hospital in Australia, marking a significant milestone for ImmutepGlobal ...

immutep-announces-tacti-004-phase-iii-trial-poster-presentation-for-eftilagimod-alfa-in-combination-with-keytruda-and-chemotherapy-for-750-advanced-nsclc-patients-across-150-sites-in-25-countries-at-elcc-march-26-29-2025
Immutep Announces TACTI-004 Phase III Tria...
03/20/2025 12:04:14

Immutep Limited ((ASX: IMM, NASDAQ:IMMP) ("Immutep" or "the Company"), a late-stage immunotherapy company targe...

immutep-completes-enrolment-of-40-patients-in-phase-ii-eftisarc-neo-trial-evaluating-efti-with-radiotherapy-and-keytruda-for-soft-tissue-sarcoma-data-updates-expected-in-2025-achieved-a-three-fold-increase-in-tumour-hyalinizationfibrosis-no-grade-3-toxicities-reported
Immutep Completes Enrolment Of 40 Patients...
01/22/2025 13:08:16

Phase II trial evaluating efti in combination with radiotherapy plus KEYTRUDA® (pembrolizumab) in patients with soft tissue sar...

immutep-reported-patient-enrolment-completed-for-eftisarc-neo-phase-ii-trial
Immutep Reported Patient Enrolment Complet...
01/22/2025 00:04:39

Immutep Limited ((ASX: IMM, NASDAQ:IMMP) ("Immutep" or "the Company"), a clinical-stage biotechnology company d...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION